These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 24914324)

  • 1. Optimal treatment strategy for Helicobacter pylori: era of antibiotic resistance.
    Heo J; Jeon SW
    World J Gastroenterol; 2014 May; 20(19):5654-9. PubMed ID: 24914324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second-line rescue treatment of
    Lin TF; Hsu PI
    World J Gastroenterol; 2018 Oct; 24(40):4548-4553. PubMed ID: 30386104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel and Effective Therapeutic Regimens for
    Hu Y; Zhu Y; Lu NH
    Front Cell Infect Microbiol; 2017; 7():168. PubMed ID: 28529929
    [No Abstract]   [Full Text] [Related]  

  • 4. A new look at anti-Helicobacter pylori therapy.
    Chuah SK; Tsay FW; Hsu PI; Wu DC
    World J Gastroenterol; 2011 Sep; 17(35):3971-5. PubMed ID: 22046084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics?
    Branquinho D; Almeida N; Gregório C; Cabral JE; Casela A; Donato MM; Tomé L
    BMC Gastroenterol; 2017 Feb; 17(1):31. PubMed ID: 28202013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
    Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
    Dig Liver Dis; 2016 May; 48(5):506-511. PubMed ID: 26847964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection.
    Gisbert JP; Molina-Infante J; Marin AC; Vinagre G; Barrio J; McNicholl AG
    Scand J Gastroenterol; 2013 Jun; 48(6):652-6. PubMed ID: 23556551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments.
    Gisbert JP; Romano M; Gravina AG; Solís-Muñoz P; Bermejo F; Molina-Infante J; Castro-Fernández M; Ortuño J; Lucendo AJ; Herranz M; Modolell I; Del Castillo F; Gómez J; Barrio J; Velayos B; Gómez B; Domínguez JL; Miranda A; Martorano M; Algaba A; Pabón M; Angueira T; Fernández-Salazar L; Federico A; Marín AC; McNicholl AG
    Aliment Pharmacol Ther; 2015 Apr; 41(8):768-75. PubMed ID: 25703120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication).
    Marin AC; McNicholl AG; Gisbert JP
    Expert Opin Pharmacother; 2013 May; 14(7):843-61. PubMed ID: 23537368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection.
    Gisbert JP; Perez-Aisa A; Rodrigo L; Molina-Infante J; Modolell I; Bermejo F; Castro-Fernández M; Antón R; Sacristán B; Cosme A; Barrio J; Harb Y; Gonzalez-Barcenas M; Fernandez-Bermejo M; Algaba A; Marín AC; McNicholl AG;
    Dig Dis Sci; 2014 Feb; 59(2):383-9. PubMed ID: 24126798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reconciliation of Recent Helicobacter pylori Treatment Guidelines in a Time of Increasing Resistance to Antibiotics.
    Fallone CA; Moss SF; Malfertheiner P
    Gastroenterology; 2019 Jul; 157(1):44-53. PubMed ID: 30998990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tailored Helicobacter pylori eradication based on prior intake of macrolide antibiotics allows the use of triple therapy with optimal results in an area with high clarithromycin resistance.
    Valle Muñoz J; Muñoz Gómez P; Sierra Bernal C; de Andrés E; Gómez Hernando C; Gómez Rodríguez R
    Rev Esp Enferm Dig; 2019 Sep; 111(9):655-661. PubMed ID: 31345044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of second-line regimens for
    Chang YL; Tung YC; Tu YK; Yeh HZ; Yang JC; Hsu PI; Kim SE; Wu MF; Liou WS; Shiu SI
    BMJ Open Gastroenterol; 2020 Sep; 7(1):. PubMed ID: 32883715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
    Fu W; Song Z; Zhou L; Xue Y; Ding Y; Suo B; Tian X; Wang L
    Dig Dis Sci; 2017 Jun; 62(6):1580-1589. PubMed ID: 28391418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toward population specific and personalized treatment of Helicobacter pylori infection.
    Liou JM; Chen PY; Kuo YT; Wu MS;
    J Biomed Sci; 2018 Oct; 25(1):70. PubMed ID: 30285834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Helicobacter pylori eradication therapy.
    Suzuki H; Nishizawa T; Hibi T
    Future Microbiol; 2010 Apr; 5(4):639-48. PubMed ID: 20353303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of four different regimens against Helicobacter pylori as a first-line treatment: A prospective, cross-sectional, comparative, open trial in Chinese children.
    Zhou Y; Ye Z; Wang Y; Zhang Y; Tang Z; Yan W; Jiang Y; Huang Y
    Helicobacter; 2020 Apr; 25(2):e12679. PubMed ID: 31958193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tailored triple plus bismuth therapy based on previous antibiotic medication history for first-line Helicobacter pylori eradication: A randomized trial.
    Song Z; Suo B; Tian X; Ren X; Xue Y; Niu Z; Zhou L
    Dig Liver Dis; 2023 May; 55(5):601-607. PubMed ID: 36646526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication.
    Tanabe H; Yoshino K; Ando K; Nomura Y; Ohta K; Satoh K; Ichiishi E; Ishizuka A; Otake T; Kohgo Y; Fujiya M; Okumura T
    Ann Clin Microbiol Antimicrob; 2018 Jun; 17(1):29. PubMed ID: 29950163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Helicobacter pylori treatment: Still a work in progress.
    Senatore FJ; Wilmot J; Birk JW
    Postgrad Med; 2016 Jan; 128(1):152-7. PubMed ID: 26490697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.